Log In Sign up
The largest database of trusted experimental protocols

Etesevimab

Manufactured by Eli Lilly
Visit Supplier

Etesevimab is a laboratory reagent produced by Eli Lilly for use in research applications. It is an antibody that can be used to detect or quantify the presence of a specific target molecule in a sample.

Automatically generated - may contain errors

Lab products found in correlation

Bamlanivimab, by Eli Lilly (2 mentions) Cilgavimab, by AstraZeneca (2 mentions) Tixagevimab, by AstraZeneca (2 mentions) Casirivimab, by Regeneron Pharmaceuticals (1 mentions) Imdevimab, by Regeneron Pharmaceuticals (1 mentions)

2 protocols using etesevimab

1

Assessment of SARS-CoV-2 Antibody Therapies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Eighteen therapeutic antibody products and a DARPin were generously provided by different companies. Ensovibep (DARPin) was generated by Molecular Partners and in-licensed by Novartis). Amubarvimab (BRII-196), Romlusevimab (BRII-198) and the Amubarvimab:Romlusevimab combination were provided by Brii Biosciences. DZIF-10c was provided by Cologne University Hospital. Bamlanivimab, Etesevimab, Bebtelovimab and two different combinations of these were provided by Eli Lilly. Tixagevimab, Cilgavimab and the Tixagevimab:Cilgavimab combination were provided by AstraZeneca. ADG20 and ADG10 were provided by Adagio Therapeutics Inc. C-144 was provided by Bristol-Myers Squibb. REGEN-COV was provided by Regeneron Pharmaceuticals. Anti-COVID-19 hIVIG was provided by Grifols and IgG-Emergent was provided by Emergent BioSolutions.
Lusvarghi S., Pollett S.D., Neerukonda S.N., Wang W., Wang R., Vassell R., Epsi N.J., Fries A.C., Agan B.K., Lindholm D.A., Colombo C.J., Mody R., Ewers E.C., Lalani T., Ganesan A., Goguet E., Hollis-Perry M., Coggins S.A., Simons M.P., Katzelnick L.C., Wang G., Tribble D.R., Bentley L., Eakin A.E., Broder C.C., Erlandson K.J., Laing E.D., Burgess T.H., Mitre E, & Weiss C.D. (2022). SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies. Science Translational Medicine.
+ Open protocol
+ Expand
2

Evaluation of Therapeutic Antibodies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Regdanvimab (CT-P59) was provided by Celltrion. Vir-7831 sotrovimab was provided by GSK (GlaxoSmithKline). The others antibodies: Bamlanivimab and Etesevimab (Eli Lilly and Company), Casirivimab and Imdevimab (Regeneron pharmaceuticals), Cilgavimab and Tixagevimab (AstraZeneca) were obtained from hospital pharmacy of the University hospital of La Timone (Marseille, France).
Touret F., Baronti C., Bouzidi H.S, & de Lamballerie X. (2022). In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. Scientific Reports, 12, 4683.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!